S
Sarah G. Hymowitz
Researcher at Genentech
Publications - 99
Citations - 13981
Sarah G. Hymowitz is an academic researcher from Genentech. The author has contributed to research in topics: Receptor & Apoptosis. The author has an hindex of 46, co-authored 96 publications receiving 12550 citations. Previous affiliations of Sarah G. Hymowitz include University of California, Davis & Wayne State University.
Papers
More filters
Journal ArticleDOI
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers,Joel D. Leverson,Erwin R. Boghaert,Scott L. Ackler,Nathaniel D. Catron,Jun Chen,Brian D. Dayton,Hong Ding,Sari H. Enschede,Wayne J. Fairbrother,David C.S. Huang,David C.S. Huang,Sarah G. Hymowitz,Sha Jin,Seong Lin Khaw,Seong Lin Khaw,Peter Kovar,Lloyd T. Lam,Jackie Lee,Heather Maecker,Kennan C. Marsh,Kylie D. Mason,Kylie D. Mason,Kylie D. Mason,Michael J. Mitten,Paul Nimmer,Anatol Oleksijew,Chang H. Park,Cheol-Min Park,Cheol-Min Park,Darren C. Phillips,Andrew W. Roberts,Andrew W. Roberts,Andrew W. Roberts,Deepak Sampath,John F. Seymour,John F. Seymour,Morey L. Smith,Gerard M. Sullivan,Stephen K. Tahir,Chris Tse,Michael D. Wendt,Yu Xiao,John Xue,Haichao Zhang,Rod A. Humerickhouse,Saul H. Rosenberg,Steven W. Elmore +47 more
TL;DR: The re-engineering of navitoclax is reported to create a highly potent, orally bioavailable and BCL-2–selective inhibitor, ABT-199, which inhibits the growth of BCL–dependent tumors in vivo and spares human platelets, indicating that selective pharmacological inhibition of Bcl-2 shows promise for the treatment of B CL-2-dependent hematological cancers.
Journal ArticleDOI
Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and Disease
TL;DR: The IL-10 family of cytokines consists of nine members that can promote innate immune responses from tissue epithelia to limit the damage caused by viral and bacterial infections and facilitate the tissue-healing process in injuries caused by infection or inflammation.
Journal ArticleDOI
Therapeutic antibody targeting of individual Notch receptors
Yan Wu,Carol Cain-Hom,Lisa Choy,Thijs J. Hagenbeek,Gladys P. de Leon,Yongmei Chen,David Finkle,Rayna Venook,Xiumin Wu,John B. Ridgway,Dorreyah Schahin-Reed,Graham J. Dow,Amy L. Shelton,Scott Stawicki,Ryan J. Watts,Jeff Zhang,Robert Choy,Peter Howard,Lisa C. Kadyk,Minhong Yan,Jiping Zha,Christopher A. Callahan,Sarah G. Hymowitz,Christian W. Siebel +23 more
TL;DR: The studies emphasize the value of paralogue-specific antagonists in dissecting the contributions of distinct Notch receptors to differentiation and disease and reveal the therapeutic promise in targeting Notch1 and Notch2 independently.
Journal ArticleDOI
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
Klaus W. Wagner,Elizabeth Punnoose,Thomas Januario,David A. Lawrence,Robert M. Pitti,Kate Lancaster,Dori Lee,Melissa von Goetz,Sharon Yee,Klara Totpal,Ling Huw,Viswanatham Katta,Guy Cavet,Sarah G. Hymowitz,Lukas C. Amler,Avi Ashkenazi +15 more
TL;DR: A new link between death-receptor O-glycosylation and apoptotic signaling is uncovered, providing potential predictive biomarkers for Apo2L/TRAIL-based cancer therapy.
Journal ArticleDOI
IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding
Sarah G. Hymowitz,Ellen Filvaroff,Jianping Yin,James Lee,Liping Cai,Philip Risser,Miko Maruoka,Weiguang Mao,Jessica Foster,Robert F. Kelley,Guohua Pan,Austin L. Gurney,Abraham M. de Vos,Melissa A. Starovasnik +13 more
TL;DR: A novel human IL‐17F homolog is reported, and it is shown that it is expressed by activated T cells, can stimulate production of other cytokines such as IL‐6, IL‐8 and granulocyte colony‐stimulating factor, and can regulate cartilage matrix turnover.